Acute myocardial infarction in young patients: nutritional status and biochemical factors

Anna Vittoria Mattioli1, Lorenzo Bonetti, Mauro Zennaro

  • 1Department of Cardiology, University of Modena and Reggio Emilia, Via del pozzo, 71, 41100 Modena, Italy. mattioli.annavittoria@unimo.it

Insights

Younger patients with acute myocardial infarction (AMI) showed similar acute-phase reactants but higher levels of homocysteine, LDL, and triglycerides compared to older patients. Nutritional status also differed significantly between the age groups.

Area of Science:

  • Cardiology
  • Biochemistry
  • Nutritional Science

Background:

  • Acute myocardial infarction (AMI) affects individuals across all age groups.
  • Understanding age-related differences in AMI patient profiles is crucial for tailored treatment strategies.
  • Biochemical markers and nutritional status may play distinct roles in the pathophysiology of AMI in younger versus older populations.

Purpose of the Study:

  • To compare nutritional status and biochemical factors, including C-reactive protein (CRP), serum amyloid A (SAA), serum iron (Fe), and fibrinogen, at admission between young (<40 years) and old (>60 years) male patients with AMI.
  • To investigate differences in the increase of acute-phase reactants during hospitalization between young and old AMI patients.
  • To examine disparities in dyslipidemic profiles between these two age groups.

Main Methods:

  • The study included 40 young male AMI patients (mean age 36.7 years) and 40 older male AMI patients (mean age 66.3 years).
  • CRP, SAA, Fe, and fibrinogen levels were measured at admission and daily for seven days.
  • Nutritional status, homocysteine, LDL, and triglyceride levels were also assessed.

Main Results:

  • Acute-phase reactants (CRP, SAA, Fe, fibrinogen) showed quantitatively similar levels between young and old AMI patients.
  • Younger patients exhibited significantly higher levels of homocysteine, LDL, and triglycerides compared to older patients.
  • Nutritional status was also found to be significantly different between the young and old AMI patient groups.

Conclusions:

  • While acute-phase reactants do not significantly differentiate young from old AMI patients, other factors do.
  • Younger AMI patients present with distinct biochemical profiles, including elevated homocysteine, LDL, and triglycerides, alongside differing nutritional status.
  • These findings highlight the importance of considering age-specific risk factors and metabolic profiles in managing acute myocardial infarction.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...